Acadia Pharmaceuticals Inc. vs. Johnson & Johnson
Acadia Pharmaceuticals Inc. (ACAD) comes out ahead, leading on 5 of 9 compared factors.
Size & Scale
| ACAD | JNJ | |
|---|---|---|
| Market Cap | $3.56 billion | $653.61 billion |
| Revenue (TTM) | $1.14 billion | $97.93 billion |
| Net Income (TTM) | $380.48 million | $21.04 billion |
JNJ leads on 3 of 3 size & scale factors.
Valuation
| ACAD | JNJ | |
|---|---|---|
| P/E Ratio | 9.27 | 31.59 |
| Price / Book | 2.73 | 7.69 |
| Price / Sales | 3.13 | 6.67 |
ACAD leads on 3 of 3 valuation factors.
Profitability
| ACAD | JNJ | |
|---|---|---|
| Net Margin | 33.42% | 21.48% |
| Return on Equity | 29.12% | 24.76% |
ACAD leads on 2 of 2 profitability factors.
Dividend
| ACAD | JNJ | |
|---|---|---|
| Dividend Yield | — | 1.97% |
| Payout Ratio | — | 62.18 |
ACAD and JNJ split the dividend factors evenly.
Risk & Sentiment
| ACAD | JNJ | |
|---|---|---|
| Short Interest | 5.74% | 0.67% |
JNJ leads on 1 of 1 risk & sentiment factors.
Dig deeper: ACAD overview, ACAD financials, JNJ overview, JNJ financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.